Skip to content

Study · Animal study (in vivo) · mouse · 2017

2 results

Phenylquinoxalinone CFTR activator as potential prosecretory therapy for constipation.

Cil O, Phuan PW, Son JH, Zhu JS, Ku CK, Tabib NA, Teuthorn AP, Ferrera L, Zachos NC, Lin R, Galietta LJV, Donowitz M, Kurth MJ, Verkman AS

Translational research : the journal of laboratory and clinical medicine15 Oct 2016Cited by 20 (Europe PMC)

PMID27815136 (opens in a new tab)PMCIDPMC5453637 (opens in a new tab)DOI10.1016/j.trsl.2016.10.003 (opens in a new tab)PepBankPUB-27815136
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In the animal study, linaclotide produced less intestinal fluid secretion than CFTRact-J027.

    In plain wordsIn mice, linaclotide produced less intestinal fluid secretion than CFTRact-J027.

    Peptide
    Linaclotide
    Outcome
    DecreaseIntestinal fluid secretion
    Study

    mousen: not reported in source

    constipation model
    Comparator
    CFTRact-J027
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Direct comparison with the approved prosecretory drugs lubiprostone and linaclotide showed substantially greater intestinal fluid secretion with CFTRact-J027, as well as greater efficacy in a constipation model.
    1 context sentence
    Summary · context
    Here, we report phenylquinoxalinone structure-activity analysis, mechanism of action, animal efficacy data in acute and chronic models of constipation, and functional data in ex vivo primary cultured human enterocytes.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In a mouse constipation model, linaclotide showed less efficacy than CFTRact-J027.

    In plain wordsIn mice with constipation, linaclotide showed less efficacy than CFTRact-J027.

    Peptide
    Linaclotide
    Outcome
    DecreaseConstipation efficacy
    Study

    mousen: not reported in source

    constipation model
    Comparator
    CFTRact-J027
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Direct comparison with the approved prosecretory drugs lubiprostone and linaclotide showed substantially greater intestinal fluid secretion with CFTRact-J027, as well as greater efficacy in a constipation model.
    1 context sentence
    Summary · context
    Here, we report phenylquinoxalinone structure-activity analysis, mechanism of action, animal efficacy data in acute and chronic models of constipation, and functional data in ex vivo primary cultured human enterocytes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.